UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____________ to _____________

Commission file number: 001-35027

BIOXYTRAN, INC.

(Exact name of registrant as specified in its charter)

Nevada

2834

26-2797630

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Code Number)

(I.R.S. Employer

Identification No.)

75 2nd Avenue, Ste 605, Needham, MA		02494
(Address of principal executive offices)		(Zip Code)

617-454-1199

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller Reporting Company	☒☐
		Emerging Growth Company	☐☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at May ~~20, 2022~~11, 2023
Common Stock, $0.001 par value per share		~~110,840,998~~130,595,578 shares

BIOXYTRAN, INC.

FORM 10-Q

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

	Item 1.	Unaudited Condensed Consolidated Financial Statements	1

		Balance Sheets as of March 31, ~~2022~~2023 and December 31, ~~2021~~2022 (Unaudited)	1

		Statements of Operations for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022 (Unaudited)	2

		Statements of Changes in Stockholders’ Deficit for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022 (Unaudited)	3

		Statements of Cash Flows for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022 (Unaudited)	4

		Notes to Unaudited Condensed Consolidated Financial Statements	5

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1517

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	1823

	Item 4.	Controls and Procedures	1823

PART II - OTHER INFORMATION

	Item 1.	Legal Proceedings	2025

	Item 1A.	Risk Factors	2025

	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2025

	Item 3.	Defaults Upon Senior Securities	2025

	Item 4.	Mine Safety Disclosures	2025

	Item 5.	Other Information	2025

	Item 6.	Exhibits	2126

SIGNATURES			2227

Except as otherwise required by the context, all references in this report to “we”, “us”, “our” or “Company” refer to the consolidated operations of BIOXYTRAN, Inc.

PART I - FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements: BIOXYTRAN, Inc., March 31, ~~2022~~2023

BIOXYTRAN, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, ~~2022~~2023 AND DECEMBER 31, ~~2021~~2022

(UNAUDITED)

	March 31, 2022			December 31, 2021			March 31, 2023			December 31, 2022
ASSETS
Current assets:
Cash	$	739,584		$	72,358		$	153,801		$	295,401
Total current assets		739,584			72,358			153,801			295,401

Intangibles, net		68,343			46,932			79,732			75,535

Total assets	$	807,927		$	119,290		$	233,533		$	370,936

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	516,139		$	624,316		$	1,100,869		$	749,395
Accounts payable related party		796,506			531,000			975,227			709,727
Un-issued shares liability		16,000			—			1,810			960
Un-issued shares liability related party		6,400			—			51,150			38,400
Convertible notes payable, net of premium and discount		3,552,225			2,122,181			2,165,000			2,165,000
Total current liabilities		4,887,270			3,277,497			4,294,056			3,663,482

Total liabilities		4,887,270			3,277,497			4,294,056			3,663,482

Commitments and contingencies		—			—			—			-

Stockholders’ deficit:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding		—			—			—			—
Common stock, $0.001 par value; 300,000,000 shares authorized; 110,840,998 issued and outstanding		110,841			110,841
Common stock, $0.001 par value; 300,000,000 shares authorized; 123,502,235 and 123,252,235 issued and outstanding as at March 31, 2023 and December 31, 2022, respectively								123,502			123,252
Additional paid-in capital		5,924,126			5,881,876			8,442,180			8,392,430
Non-controlling interest		(448,372	)		(397,256	)		(623,522	)		(590,628	)
Accumulated deficit		(9,665,938	)		(8,753,668	)		(12,002,683	)		(11,217,600	)
Total stockholders’ deficit		(4,079,343	)		(3,158,207	)		(4,060,523	)		(3,292,546	)

Total liabilities and stockholders’ deficit	$	807,927		$	119,290		$	233,533		$	370,936

See the accompanying notes to these unaudited condensed consolidated financial statements

BIOXYTRAN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, ~~2022~~2023 AND ~~2021~~2022

(UNAUDITED)

3-Months Ended
March 31,
2022 March 31,
2021
Operating expenses:
Research and development $ 240,125 $ 347,033
General and administrative 556,581 567,320
Compensation expense 22,400 774,558
Total operating expenses 819,106 1,688,911

Loss from operations (819,106 ) (1,688,911 )

Other expenses:
Interest expense 52,035 87,410
Amortization 92,245 —
Total other expenses 144,280 87,410

Net loss before provision for income taxes (963,386 ) (1,776,321 )

Provision for income taxes — —
Net loss (963,386 ) (1,776,321 )

Net loss attributable to the non-controlling interest 51,116 154,614

NET LOSS ATTRIBUTABLE TO BIOXYTRAN $ (912,270 ) $ (1,621,707 )

Loss per common share, basic and diluted $ (0.01 ) $ (0.02 )

Weighted average number of common shares outstanding, basic and diluted 110,840,998 100,118,229

	March 31, 2023			March 31, 2022
	3-Months Ended
	March 31, 2023			March 31, 2022
Operating expenses:
Research and development	$	139,004		$	240,125
General and administrative		587,638			535,861
General and administrative related party		10,000			20,720
Compensation expense		13,600			22,400
Total operating expenses		750,242			819,106

Loss from operations		(750,242	)		(819,106	)

Other expenses:
Interest expense		67,221			52,035
Amortization of IP		514			911
Amortization of debt discount		—			91,334
Total other expenses		67,735			144,280

Net loss before provision for income taxes		(817,977	)		(963,386	)

Provision for income taxes		—			—
Net loss		(817,977	)		(963,386	)

Net loss attributable to the non-controlling interest		32,894			51,116

NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$	(785,083	)	$	(912,270	)

Loss per common share, basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average number of common shares outstanding, basic and diluted		123,495,291			110,840,998

See the accompanying notes to these unaudited condensed consolidated financial statements

BIOXYTRAN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, ~~2022~~2023 AND ~~2021~~2022

(UNAUDITED)

																						Shares		Amount		Shares		Amount		Common			Preferred		Deficit			Interest			Deficit
	Common Stock				Preferred Stock				Additional Paid in Capital				Accumulated			Non-controlling			Total			Common Stock				Preferred Stock				Additional Paid in Capital					Accumulated			Non-controlling			Total
	Shares		Amount		Shares		Amount		Common		Preferred		Deficit			Interest			Deficit
December 31, 2020		97,450,673	$	97,451		0		—	$	1,795,125	$	—	$	(4,721,923	)	$	888,091		$	(1,941,256	)
Option s issued and vested - 2021 Plan										6,750										6,750
Shares issued to BoD & Mgmnt - 2010 Plan		1,366,800		1,367						326,665										328,032
Shares issued to Consultants - 2010 Plan		1,832,400		1,832						437,944										439,776
Subsidiary stock transactions																	450,000			450,000
Net loss attributable to the non-controlling interest																	(154,614	)		(154,614	)
Net loss								—						(1,621,707	)					(1,621,707	)
March 31, 2021		100,649,873	$	100,650		0		—	$	2,566,484	$	—	$	(6,343,630	)	$	1,183,477		$	(2,493,019	)
																						Shares		Amount		Shares		Amount		Common			Preferred		Deficit			Interest			Deficit
December 31, 2021		110,840,998	$	110,841		0		—	$	5,881,876	$	—	$	(8,753,668	)	$	(397,256	)	$	(3,158,207	)		110,840,998	$	110,841		—		—	$	5,881,876		$	—	$	(8,753,668	)	$	(397,256	)	$	(3,158,207	)
Issuance of Warrants										42,250										42,250											42,250											42,250
Net loss attributable to the non-controlling interest																	(51,116	)		(51,116	)																		(51,116	)		(51,116	)
Net loss				—				—						(912,270	)					(912,070	)				-				-					-		(912,270	)					(912,270	)
March 31, 2022		110,840,998	$	110,841		0		—	$	5,924,126	$	—	$	(9,665,938	)	$	(448,372	)	$	(4,079,343	)		110,840,998	$	110,841		—		—	$	5,924,126		$	—	$	(9,665,938	)	$	(448,372	)	$	(4,079,343	)

December 31, 2022																							123,252,235	$	123,252		—		—	$	8,392,430		$	—	$	(11,217,600	)	$	(590,628	)	$	(3,292,546	)
Stock transactions																							250,000		250		-				79,750											80,000
Stock subscription																															(30,000	)										(30,000	)
Net loss attributable to the non-controlling interest																																							(32,894	)		(32,894	)
Net loss																													-					-		(785,083	)					(785,083	)
March 31, 2023																							123,502,235	$	123,502		—		—	$	8,442,180		$	—	$	(12,002,683	)	$	(623,522	)	$	(4,060,523	)

See the accompanying notes to these unaudited condensed consolidated financial statements

BIOXYTRAN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, ~~2022~~2023 AND ~~2021~~2022

(UNAUDITED)

3-Months Ended
March 31,
2022 March 31,
2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (963,386 ) $ (1,776,321 )
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization 92,245 —
Stock-based compensation expense 22,400 774,558
Changes in operating assets and liabilities:
Accounts payable and accrued expenses (108,176 ) 169,673
Accounts payable related party 265,506 20,240
Other short-term debt — 420,750
Net cash used in operating activities (691,411 ) (391,100 )

CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in intangibles (22,323 ) (8,953 )
Net cash used in investing activities (22,323 ) (8,953 )

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from subsidiary stock transactions — 450,000
Proceeds from issuance of convertible notes payable 1,380,960 —
Net cash provided by financing activities 1,380,960 450,000

Net increase in cash 667,226 49,947
Cash, beginning of period 72,358 41,688
Cash, end of period $ 739,584 $ 91,635

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid $ — $ —
Income taxes paid $ — $ —
NON-CASH INVESTING & FINANCING ACTIVITIES:
Issuance of warrants $ 42,250 $ —
Debt discount on convertible note $ 86,040 $ —

	March 31, 2023			March 31, 2022
	3-Months Ended
	March 31, 2023			March 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(817,977	)	$	(963,386	)
Adjustments to reconcile net loss to net cash used in operating activities:
Debt discount amortization, incl. issuance of warrants		—			91,334
Amortization of IP		514			911
Stock-based compensation expense		13,600			22,400
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		351,473			(108,176	)
Accounts payable related party		265,500			265,506
Other short-term debt		—			—
Net cash used in operating activities		(186,890	)		(691,411	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in intangibles		(4,711	)		(22,323	)
Net cash used in investing activities		(4,711	)		(22,323	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock transactions		50,000			—
Proceeds from issuance of convertible notes payable		—			1,380,960
Net cash provided by financing activities		50,000			1,380,960

Net increase (decrease) in cash		(141,600	)		667,226
Cash, beginning of period		295,401			72,358
Cash, end of period	$	153,801		$	739,584

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	$	52,425		$	—
Income taxes paid	$	—		$	—
NON-CASH INVESTING & FINANCING ACTIVITIES:
Issuance of warrants	$	—		$	42,250
Debt discount on convertible note	$	—		$	86,040

See the accompanying notes to these unaudited condensed consolidated financial statements

BIOXYTRAN, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, ~~2022~~2023 AND ~~2021~~2022

(UNAUDITED)

NOTE 1 – BACKGROUND AND ORGANIZATION

Business Operations

Bioxytran, Inc. (the “Company”) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner.

Our Subsidiary, Pharmalectin, Inc. (the “Subsidiary”) is a clinical stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address conditions related to Covid-19.

Our Foreign Subsidiary, Pharmalectin (BVI), Inc. (the “Foreign Subsidiary”) is the owner and custodian of the Company’s Copyrights, Trade Marks and Patents.

Organization

Bioxytran, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized common shares with a par value of $0.0001, and 5,000,000 Preferred shares with a par value of $0.0001. On September 21, 2018, the Company went under a reorganization in the form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 300,000,000 authorized common shares with a par value of $0.001, and 50,000,000 Preferred shares with a par value of $0.001.

Pharmalectin was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized Common shares with a par value of $0.0001, and 5,000,000 Preferred shares with a par value of $0.0001. The Subsidiary was founded under the name of Bioxytran “Bioxytran (DE)”. On April 29, 2020, the name was changed to Pharmalectin, Inc. There are currently 30,000,000 issued and 19,650,000 outstanding shares; 15,000,000 Common shares are held by Bioxytran and 4,650,000 Common shares are held by an affiliate. An additional 4,500,000 options are also held by an affiliate. The option agreement includes provisions for dilutive issuance and cash-less exercise. The beneficial ownership of the affiliate are Mike Sheikh, Ola Soderquist and David Platt.

Pharmalectin BVI was organized on March 17, 2021 as a British Virgin Islands (BVI) Business Corporation with a BVI corporate taxing structure with 50,000 authorized shares with a par value of $1.00. There are currently 50,000 outstanding shares held by the Company.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the ~~"SEC"~~“SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("(“U.S. ~~GAAP"~~GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited consolidated financial statements.

While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of the management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company’s December 31, ~~2021~~2022 audited financial statements and notes that can be expected for the year ending December 31, 2022.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation, its majority owned subsidiary, Pharmalectin, Inc. of Delaware (collectively, the “Company”), as well as its wholly owned subsidiary, Pharmalectin (BVI), Inc of British Virgin Islands. All intercompany accounts have been eliminated upon consolidation.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.

Cash

For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with an original maturity date of three months or less to be cash equivalents.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Net Loss per Common Share, basic and diluted

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into Common Stock using the “treasury stock” and/or “if converted” methods as applicable.

At March 31, ~~2022,~~2023, we would, based on the market price of $~~0.173~~0.425/share, be obligated to issue approximately ~~23,509,009~~17,802,900 shares of Common Stock upon conversion of the currently outstanding convertible notes (the “New Notes”) and ~~536,060~~482,030 shares upon exercise of the warrants and ~~668,000~~476,000 shares upon exercise of outstanding options. For the New Notes, the shares total is based on $~~3,769,720~~2,314,377 of currently outstanding principal, and unpaid interest.

The 2021 1-year notes (the “New Notes”), have an interest rate of 6%6% and are convertible at the lower of (i) a fixed price of ~~$0.13,~~$0.13, or (ii) 85% of the closing price of any Qualified Financing, which consist of any fundraising receiving gross proceeds of not less than $500,000.

The 2022 1-year notes (the “New Notes”), have an interest rate of 6% and are convertible at a fixed price of $0.25. The New Notes are limited to converting no more than 4.99% of our issued an outstanding Common Stock.

Stock Based Compensation

The Company measures the cost of services received from employees and non-employees in exchange for an award of equity instruments based on the fair value of the award on the grant date pursuant ASC 718. Stock-based compensation expense is recorded by the Company over the requisite service period, or vesting period, in the same expense classifications in the statements of operations, as if such amounts were paid in cash.

Accounting for subsidiary stock transactions

The Company accounts for subsidiary stock transactions in accordance with Opinions of the Accounting Principles Board 09 (APBO No. 9). In paragraph 28, this pronouncement excluded all adjustments from transactions in a company’s own stock “. . . from the determination of net income or the results of operations under all circumstances.” ~~During the three months ended March 31 2021, the Company sold shares in its subsidiary Pharmalectin for a total amount of $450,000~~.~~. Accordingly, APIC was adjusted with this amount for the 3 months ended March 31, 2021, no such transactions took place during the 3 months ended March 31, 2022.~~

Research and Development

The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period

incurred. For the three months ended March 31, ~~2022~~2023 the Company incurred $~~240,125~~139,004 in research and development expenses, while during the three months ended March 31, ~~2021~~2022 the Company incurred $~~347,033~~240,125.

Intangibles – Goodwill and Other

Valuation of intangibles are in accordance with ASC 350. Costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at award date, which varies depending on the pendency period of the application, generally approximating seventeen years. Capitalized patent costs, also referred to as patent prosecution costs, include internal legal labor, professional legal fees, government filing fees and translation fees related to expanding the Company’s patent portfolio. Costs associated with the maintenance and annuity fees of patents are accounted for as prepaid assets at the time of payment and amortized over the shorter of the maintenance period or remaining life of the related patent.

Accrued Expenses

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves identifying services that third parties have performed on our behalf and estimating the level of service performed and the associated cost incurred on these services as at each balance sheet date in our consolidated financial statements. Examples of estimated accrued expenses include professional service fees, such as those arising from the services of attorneys and accountants and accrued payroll expenses. In connection with these service fees, our estimates are most affected by our understanding of the status and timing of services provided relative to the actual services incurred by the service providers. In the event that we do not identify certain costs that have been incurred or we under- or over-estimate the level of services or costs of such services, our reported expenses for a reporting period could be understated or overstated. The date on which certain services commence, the level of services performed on or before a given date, and the cost of services are often subject to our judgment. We make these judgments based upon the facts and circumstances known to us in accordance with accounting principles generally accepted in the U.S.

Warrants

The Company has issued Common Stock warrants in connection with the execution of certain equity and debt financings. The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding volatility of our common share price, remaining life of the warrant, and risk-free interest rates at each period end.

Fair Value

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.

Recent Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s financial statements.

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s unaudited condensed interim financial statements.

NOTE 3 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS

As at March 31, ~~2022,~~2023, the Company had cash of $~~739,584~~153,801 and a negative working capital of $~~4,147,687~~4,140,255. The Company has not yet generated any revenues, and has incurred cumulative net losses of $~~9,665,939~~12,002,683. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

During the three months ended March 31, 2023, the Company raised a net of $50,000 in cash proceeds from equity. During the same period in 2022, the Company raised a net of $1,380,960 in cash proceeds from the issuance of convertible notes. ~~During the same period in 2021, the Company raised $450,000~~ ~~from the issuance of common stock in our subsidiary.~~ The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of June, ~~2022~~2023 and is pursuing alternative opportunities to funding.

The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

The Company’s management does not know the full extent or foresee the impact COVID-19 has had on our business or our operations or its ability to carry out our plans. We will continue to monitor and follow this situation closely.

Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

NOTE 4 - RELATED PARTY TRANSACTIONS

The Company hold License Agreements (the “License/s” or “Agreement/s”) for a medical device (license obtained in 2019) and a compound (license obtained in 2021), with two affiliated companies where in the officers of the Company hold a majority interest. The products were developed prior to the establishment of Bioxytran. The yearly maintenance fee for each license amount to $5,000. During the three months ended March 31, 2023 the affiliates were paid $5,000 each. During the same period in 2022, there was $20,720 in transactions with affiliates as the Company also reimbursed the affiliates for the legal and administrative costs surrounding the establishment of the Licenses.

NOTE 5 - INTANGIBLES

Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. ~~NaN~~No impairment charges were recorded for the 3 months ended March 31, ~~2022~~2023 and the year ended December 31, ~~2021.~~2022.

Amortization of capitalized patent costs associated with the application and award of patents in the U.S. and various other countries are capitalized and amortized on a straight-line basis over the term of the patents as determined at the award date, which varies depending on the pendency period of the application, generally approximating twenty years.

Estimated Life
(years) March 31,
2022 December 31,
2021
Capitalized patent costs 20 $ 69,254 $ 46,931
Accumulated amortization (911 ) —

Intangible assets, net $ 68,343 $ 49,931

SCHEDULE OF INTANGIBLES

	Estimated Life (years)	March 31, 2023			December 31, 2022
Capitalized patent costs	20	$	83,890		$	79,179
Accumulated amortization			(4,158	)		3,644

Intangible assets, net		$	79,732		$	75,535

NOTE 56 – ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

On March 31, ~~2022,~~2023, there was $~~796,506~~975,227 in accounts payable to related parties in the form of payroll and accrued expenses and $~~6,400~~51,150 in un-issued shares liability related party. On December 31, ~~2021~~2022 there was $~~531,000~~709,727 in accounts payable to related ~~parties.~~parties and $38,400 in un-issued shares liability related party.

The following table represents the major components of accounts payables and accrued expenses and other current liabilities at March 31, ~~2022~~2023 and at December 31, ~~2021:~~2022:

March 31,
2022 December 31,
2021
Accounts payable related party ⁽¹⁾ $ 796,506 $ 531,000
Professional fees 120,696 375,371
Other 1,155 —
Interest 137,720 85,685
Payroll taxes 59,693 32,010
Pension/401K 196,875 131,250
Un-issued share liability, consultant 16,000 —
Un-issued share liability, related party ⁽²⁾ 6,400 —
Convertible note payable 3,552,225 2,122,181
Total $ 4,887,270 $ 3,277,497

SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

	March 31, 2023		December 31, 2022
Accounts payable related party (1)	$	975,227	$	709,727
Professional fees		656,963		393,085
Interest		149,377		134,581
Payroll taxes		45,887		40,182
Pension/401K		246,182		180,557
Other		2,460		990
Un-issued share liability, related party (2)		51,150		38,400
Un-issued share liability, consultant		1,810		960
Convertible note payable		2,165,000		2,165,000
Total	$	4,294,056	$	3,663,482

(1)

$~~315,000~~ 391,900to ~~each~~the CEO, $374,400 to the CFO and $208,927 and the ~~CEO~~CCO for 2311 months of ~~salary and $166,506 to the VPBD for salary and expenses.~~salary. At December 31, ~~2021~~2022 there ~~was $210,000~~were $286,900 to ~~each~~the CEO, $269,400 to the CFO and $153,427 and the ~~CEO $111,000 to the VPBD for salary and expenses.~~CCO. All earlier accrued salaries due were forfeited on August 1, 2022.

(2)

There are currently ~~40,000~~60,000 shares of Common Stock awarded but not issued to four Board Members in the first quarter of ~~2022.~~2023. The total fair market value at the time of the award was ~~$6,400~~$51,250

NOTE 67 – CONVERTIBLE NOTES PAYABLE

Private Placement, 2021 Notes

Around ~~May 3,~~April 29, 2021, we entered into ~~four (4)~~nine (9) Securities Purchase Agreements ~~or “the~~(the “2021 SPA’s”), under which we agreed to sell convertible promissory notes ~~“the~~(the “2021 Notes”), in an aggregate principal amount of $~~2,165,000~~3,266,845 with6% ~~interest.~~interest, whereof $1,000,000 were contributed in form of cancellation of third-party notes, while 1,101,846 were issued in compensation for accrued compensation, $981,466 to our three officers and $120,380 to two consultants.

At any time after the issue date of the Notes, The Holders of the Notes, ~~“the~~(the “2021 Holders”), have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the 2021 Notes into shares of our ~~common stock~~Common Stock at the Conversion Price. The “Conversion Price” will be the lesser of (i) $.13 per share or (ii) 85% of the closing price of Any Qualified Financing, which consists of any fundraising ~~receiving~~whereby the Company receives gross proceeds of not less than ~~$500,000.~~$500,000.

The variable conversion rate component requires that the 2021 Notes to be valued at its stock redemption value (i.e., “if-converted” value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the 2021 Notes. No such recording of a premium was required as the discounted “if-converted” rate of $0.13 per share, was identical to fair market value of the Company’s stock on the 2021 Notes date of issuance.

The 2021 Holders are limited to holding a total of 4.99% of our issued and outstanding ~~common stock.~~Common Stock at any one time.

The Common Stock underlying the 2021 Notes, when issued, will bear a restrictive legend and ~~has~~have a 180-day lock-up period. ~~They are currently eligible~~

On June 4, 2021, 8,522,125 shares of Common Stock were issued as a result of conversion of accrued interest and principal for ~~resale under Rule 144.~~five convertible notes for a total of $1,101,846, or $0.13/share. To avoid dilution of the company’s stock 7,591,261 of these shares held by our officers were returned to treasury on November 20, 2021, while the original debt consisting of accrued salary was forfeited.

SCHEDULE OF CONVERTIBLE CONVERSION OF ACCRUED INTEREST AND PRINCIPAL

Name		Principal Converted		Accrued interest converted		No. of shares issued
Private Placement, 2021 Notes issued to Officers	(1)	$	981,466	$	5,398		7,591,261
Private Placement, 2021 Notes issued to consultants			120,380		662		930,864
		$	1,101,846	$	6,060		8,522,125

(1)	Net cash received for these notes were $1,380,960, after a Debt Discount of $86,040 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).

If the remainder of the 2021 Notes are converted prior to us paying off such note, it would lead to substantial dilution to our shareholders as a result of the conversion discounted ~~for~~applicable to the 2021 Notes. There can be no assurance that there will be any funds available to pay of the ~~Notes, or if available, on terms that will be acceptable to us or our shareholders.~~2021 Notes. If we fail to obtain such additional financing on a timely basis, the 2021 Holders may convert the 2021 Notes and sell the underlying shares, which may result in significant dilution to shareholders due to the conversion discount, as well as a significant decrease in our stock price.

Convertible notes payable and interest payable consist of the following at March 31, 2023, and December 31, 2022:

SCHEDULE OF CONVERTIBLE NOTES PAYABLE

	March 31, 2023		December 31, 2022
Principal balance (1), (2)	$	2,165,000	$	2,165,000
Interest Payable		149,377		134,581
Outstanding, net of debt discount and premium	$	2,314,377	$	2,299,581

(1)	Net cash received for these notes were $1,045,150, after a Debt Discount of $119,850 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).
(2)	$2 million of principal, accrued interest and default penalties for notes issued prior to 2021, where settled by a third party in exchange for us issuing to them a note in the amount of $1 million.

Private Placement, 2022 Notes converted into Common Stock

~~Throughout the quarter,~~In January, 2022, we entered into thirty-four (34) Securities Purchase Agreements ~~or “the~~(the “2022 SPA’s”), with accredited investors, under which we agreed to sell the Notes, in an aggregate principal amount of $1,467,000 with 6% interest (the “2022 Notes”) to the ~~Holders~~holders of the 2022 Notes ~~“the~~(the “2022 Holders”).

At any time after the issue date of the 2022 Notes ~~“the Holders”,~~the 2022 Holders have the option to convert all or any part of the outstanding and unpaid principal amount and accrued and unpaid interest of the Notes into shares of our Common Stock at the Conversion Price. The “Conversion Price” is set to ~~$0.25~~$0.25 per share.

The 2022 Holders are limited to holding a total of ~~4.99%~~4.99% of our issued and outstanding Common ~~Stock.~~Stock at any one time. The Common Stock underlying the 2022 Notes, when issued, bear a restrictive legend and are currently eligible for resale under Rule 144.

If the Notes are converted prior to us paying off such note, it would lead to dilution to our shareholders as a result of the conversion discounted for the Notes. There can be no assurance that there will be any funds available to pay of the Notes, or if available, on terms that will be acceptable to us or our shareholders. If we fail to obtain such additional financing on a timely basis, the Holders may convert the Notes and sell the underlying shares, which may result in dilution if converted, as well as a decrease in our stock price.

~~Schedule~~The notes principal and accrued interest were fully converted into 6,081,484 shares of ~~converted notes~~Common Stock on August 31, 2022.

Name
Principal due
March 31, 2022

Accrued interest
March 31, 2022

Total amount due
March 31, 2022
Private Placement, 2021 Notes (1) $ 2,165,000 $ 118,160 2,283,160
Private Placement, 2022 Notes (2) 1,467,000 19,560 1,486,560
$ 3,632,000 $ 137,720 3,769,720

⁽¹⁾ $1,000,000 of this amount was used to extinguish the Old Notes. Net cash received for these notes were $1,045,150, after a Debt Discount of $119,850 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).
⁽²⁾ Net cash received for these notes were $1,380,960, after a Debt Discount of $86,040 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).

~~At December 31, 2021 the outstanding convertible notes were as follows:~~

Name
Principal due
December 31, 2021

Accrued interest
December 31, 2021

Total amount due
December 31, 2021
Notes sold in exchange for cash (1) $ 1,165,000 $ 46,108 1,211,108
Note issued in exchange for defaulted Old Notes (2) 1,000,000 39,577 1,039,577
$ 2,165,000 $ 85,685 2,250,685

(3) Net cash received for these notes were $1,045,150, after a Debt Discount of $119,850 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).
(4) The "Old Notes" were paid off and assumed by a different entity/company. Portions of the balance was forgiven and a new note of $1,000,000 was issued.

~~Convertible notes payable consists of the following at March 31, 2022 and December 31, 2021:~~

Name		Principal Converted		Accrued interest converted		No. of shares issued
Private Placement, 2022 Notes	(1)	$	1,467,000	$	53,371		6,081,484
		$	1,467,000	$	53,371		6,081,484

March 31,
2022 December 31,
2021
Principal balance $ 3,632,000 $ 2,165,000
Unamortized debt discount (79,775 ) (42,819 )
Outstanding, net of debt discount and premium $ 3,552,225 $ 2,122,181

(1)	Net cash received for these notes were $1,380,960, after a Debt Discount of $86,040 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).

NOTE 78 – STOCKHOLDERS’ EQUITY

The Company is authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock.

Preferred stock

As ofat March 31, ~~2022, or December 31, 2021,~~ 2023, no preferred shares have been designated nor issued.

Common stock

~~For the 3 months ending March 31, 2021,~~ ~~1,366,800~~ ~~shares were awarded to the board of directors~~As at January 1, 2022, and ~~management under the 2010 Stock Plan for a total value of $328,032~~.

~~For the 3 months ending March 31, 2021,~~ ~~1,832,400~~ ~~shares were awarded to consultants under the 2010 Stock Plan for a total value of $439,776~~.

~~As of~~at March 31, 2022 the Company ~~has~~had 110,840,998 shares of common stock issued and outstanding. ~~At December 31, 2021~~

As at January 1, 2023 there were ~~110,840,998~~123,252,235 shares of common stock issued and outstanding.

On January 4, 2023 the Company issued 93,750 shares of Common Stock against $30,000, or $0.32/share, shown as stock subscription in the December 31, 2022 stockholders’ equity statement.

On February 10,

2023 the Company issued 156,250 shares of Common Stock against $50,000, or $0.32/share

As at March 31, 2023, the Company has 123,502,235 shares of common stock issued and outstanding.

Common Stock Warrants

For the 3 months ended March 31, 2023 the Company did not issue any Warrants. For the 3 months ended March 31, 2022, in connection with the issuance of the convertible notes, the Company issued 264,060 ~~5-year~~5-year warrants exercisable at $0.25/share, valued at $0.16, based on Black and Scholes Option Pricing Model, for a total value of $42,250. ~~For the 3 months ended March 31, 2021 the Company did not issue any Warrants.~~

The fair value of stock warrants granted for the 3 months ended March 31, 2022 was calculated with the following assumptions:

SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS

	March 31, 2022
Risk-free interest rate		March 31, 20221.53	%
~~Risk-free interest rate~~Expected dividend yield		0	%
Volatility factor (monthly)		169.27	%
Expected life of warrant		~~1.53~~	%
~~Expected dividend yield~~				0	%
~~Volatility factor (monthly)~~				~~169.27~~	%
~~Expected life of warrant~~				5 years

The following table summarizes the Company’s common stock warrant activity for the 3 months ended March 31, ~~2022~~2023 and ~~2021:~~2022:

Number of
Warrants Weighted
Average
Exercise
Price Weighted-
Average
Remaining
Expected
Term
Outstanding as at December 31, 2021 272,000 $ 2.00 3.9
Granted — — —
Exercised — — —
Forfeited/Canceled — — —
Outstanding as at March 31, 2021 272,000 2.00 3.7

Outstanding as at December 31, 2022 272,000 $ 2.00 2.9
Granted 264,060 0.25 5.0
Exercised — — —
Forfeited/Canceled — — —
Outstanding as at March 31, 2022 536,060 $ 1.14 3.7

SCHEDULE OF WARRANT ACTIVITY

	Number of Warrants*		Weighted Average Exercise Price		Weighted- Average Remaining Expected Term
Outstanding as at January 1, 2022		272,000	$	2.00		2.9
Granted		264,030		0.26		5.0
Exercised		—		—		—
Forfeited/Canceled		—		—		—
Outstanding as at March 31, 2022		536,030		1.14		3.7

Outstanding as at January 1, 2023		542,030	$	0.42		4.1
Granted		—		—		—
Exercised		—		—		—
Forfeited/Canceled		—		—		—
Outstanding as at March 31, 2023		542,030	$	1.14		3.8

The warrant agreements issued in 2019 for a total of 50,000 warrants include provisions for dilutive issuance and cash-less exercise. If exercised at December 31, 2022 the provisions would have resulted in an issuance of 1,130,114 shares at an average conversion price of $0.09, or 1,050,114 shares in a cash-less exercise. In order to mitigate the Company’s risk an administrative hold has been placed on one shareholder’s stock in the event of future exercise.

The following table summarizes information about stock warrants that are vested or expected to vest at March 31, ~~2022:~~2023:

Warrants Outstanding Exercisable Warrants
Number of
Warrants Weighted
Average
Exercise
Price
Per Share Weighted
Average
Remaining
Contractual
Life (Years) Aggregate
Intrinsic
Value Number of
Warrants Weighted
Average
Exercise
Price Per
Share Weighted
Average
Remaining
Contractual
Life (Years) Aggregate
Intrinsic
Value
264,060 0.25 4.8 $ — 264,060 0.25 4.8 $ —
272,000 $ 2.00 2.6 $ — 272,000 $ 2.00 2.6 $ —
536,060 $ 1.14 3.7 $ — 536,060 $ 1.14 3.7 $ —

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS

		Warrants Outstanding								Exercisable Warrants
Number of Warrants		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value		Number of Warrants		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
	492,030		0.26		4.1	$	81,184		492,030		0.26		4.1	$	81,184
	50,000	$	2.00		1.6	$	—		50,000	$	2.00		1.6	$	—
	542,030	$	1.14		3.9	$	81,184		542,030	$	1.14		3.9	$	81,184

There were no warrants issued for the three months ended at March 31, 2023. The following table sets forth the status of the Company’s non-vested warrants as at March 31, ~~2022, there were no warrants issued for the three months ended at March 31, 2021:~~2022:

Number of
Warrants Weighted-
Average
Grant-Date
Fair Value
Non-vested as at December 31, 2022 — $ —
Granted 264,060 0.25
Forfeited 0 0
Vested 264,060 0.25
Non-vested as at March 31, 2022 0 $ 0

~~The weighted-average remaining contractual life for warrants exercisable at March 31, 2022 is~~ ~~3.65~~SCHEDULE OF NON-VESTED WARRANTS ~~years. The aggregate intrinsic value for fully vested, exercisable warrants was $~~0 ~~at March 31, 2022 and at December 31, 2021~~.

~~Sales of Shares in Subsidiary~~

~~For the 3 months ended March 31, 2022 there were no shares sold in the Company’s Subsidiary, Pharmalectin, Inc.. For the 3 months ended March 31, 2021 there were~~ ~~1,350,000~~ ~~shares sold in the Company’s Subsidiary, Pharmalectin, Inc. for a total of $450,000~~.

	Number of Warrants		Weighted-Average Grant-Date Fair Value
Non-vested as at January 1, 2022		—	$	—
Granted		264,030		0.25
Forfeited		—		—
Vested		—		—
Non-vested as at March 31, 2022		264,030	$	0.25

NOTE 89 – STOCK OPTION PLAN AND STOCK-BASED COMPENSATION

On January 19, 2010, the Company adopted a stock option plan entitled “The 2010 Stock Plan” (2010 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to 15% of common stock, automatically adjusted on January 1 each year. Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance.

As at January 18, 2021, the 2010 plan was retired and depleted. On January 19, 2021, “The 2021 Stock Plan” (2021 Plan) with the same terms as the 2010 Plan.

Shares Awarded and Issued under the 2010 Plan:

On January 1, 2021 the Company granted 10,000 shares, with a fair market value of $0.24/share at the time of award, to a Medical Advisory Board Member for her contribution in the Company’s Advisory Board, for a total of $2,400.

On January 15, 2021 the Company granted 3,189,200 shares of Common Stock valued at $0.24/share, equally divided to 227,800 shares/each to fourteen of the Company’s Managers, Board- and Medical Advisory Board members, as well as to indispensable Consultants currently working on the clinical trial submissions with the FDA, for a total value of ~~$765,408.~~$765,408.

Number of
Shares
Fair Value
per Share Weighted Average
Market Value
per Share
Shares Issued as of December 31, 2020 11,002,000 $ 0.003 – 1.49 $ 0.10
Shares Issued 3,199,200 0.24 0.24
Shares Issued as of March 31, 2021 14,201,200 $ 0.003 – 1.49 $ 0.13

Shares Issued as of December 31, 2021 18,706,909 0.003 – 1.49 0.088
Shares Issued — — —
Shares Issued as of March 31, 2022 18,706,909 $ 0.003 – 1.49 $ 0.088

SCHEDULE OF FAIR MARKET VALUE

	Number of Shares		Fair Value per Share		Weighted Average Market Value per Share
Shares Issued as of January 1, 2022		18,706,909		0.003 – 1.49		0.088
Shares Issued		—		—		—
Shares Issued as of March 31, 2022		18,706,909	$	0.003 – 1.49	$	0.088

Shares Issued as of January 1, 2023		19,382,909		0.003 – 1.49		0.095
Shares Issued		—		—		—
Shares Issued as of March 31, 2023		19,382,909	$	0.003 – 1.49	$	0.095

For the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, the Company recorded stock-based compensation expense of $~~22,400~~13,600 and $~~774,558~~22,400, respectively, in connection with share-based payment awards.

Shares awarded, but not yet issued, under the 2021 Stock ~~Plan:~~Plan for the three months ended March 31, 2023 and 2022:

On January 10, 2022 the Company granted 40,000 shares of Common Stock to four Board Members in reward of their attendance at Board and Committee meetings during the fourth quarter of 2021. The total fair market value at the time of the award was $6,400, or $0.16/share.

On ~~February 18, 2022~~January 1, 2023 the Company granted ~~100,000~~80,000 shares of Common Stock to ~~two Consultants~~four Board Members in reward of their ~~assistance for~~attendance at Board and Committee meetings during the ~~product development and our clinical trials in India.~~fourth quarter of 2022. The total fair market value at the time of the award was $~~16,000~~38,400, or $~~0.16~~0.48/share.

On January 1, 2023 the Company granted 2,000 shares of Common Stock to an Advisory Board Members in compensation for the fourth quarter of 2022. The total fair market value at the time of the award was $960, or $0.48/share.

On March 31, 2023 the Company granted 30,000 shares of Common Stock to four Board Members in reward of their attendance at Board and Committee meetings during the first quarter of 2023. The total fair market value at the time of the award was $12,750, or $0.425/share.

On March 31, 2023 the Company granted 2,000 shares of Common Stock to an Advisory Board Members in compensation for the first quarter of 2023. The total fair market value at the time of the award was $850, or $0.425/share.

Stock options granted and vested 2021 Plan:

~~On February 1, 2021 the Company granted~~ ~~45,000~~ ~~three-year options immediately vested at an exercise price of $0.20~~ ~~to a Medical Advisory Board Member for his contribution in the Company’s Advisory Board. The options total fair value at the time of award was $6,750~~.

There were no stock options granted the three months ended March 31, ~~2022.~~ ~~The fair value of stock options granted~~2023 and ~~revaluation of non-employee consultant options for the three months ended March 31, 2021 was calculated with the following assumptions:~~2022.

	~~March 31, 2021~~
~~Risk-free interest rate~~		~~0.17~~	%
~~Expected dividend yield~~		0	%
~~Volatility factor (monthly)~~		~~161.18~~	%
~~Expected life of options~~		~~3 years~~

There were no stock options granted the three months ended March 31, 2022. For the three months ended March 31, 2021, the Company recorded compensation expense of $6,750 in connection with awarded stock options. As at March 31, 2022, there was no unrecognized compensation expense related to non-vested stock option awards.

The following table summarizes the Company’s stock option activity for the three months ended March 31, ~~2022,~~2023, and ~~2021:~~2022:

Number of Options Exercise
Price per
Share Weighted
Average
Exercise
Price
per Share
Outstanding as of December 31, 2020 533,000 $ 0.001 - 1.21 $ 0.73
Granted 45,000 0.20 0.20
Exercised — — —
Options forfeited/cancelled — — —
Outstanding as of March 31, 2021 578,000 $ 0.001 - 1.21 $ 0.72

Outstanding as of December 31, 2021 668,000 $ 0.001 - 1.21 $ 0.55
Granted — — —
Exercised — — —
Options forfeited/cancelled — — —
Outstanding as of March 31, 2022 668,000 $ 0.001 - 1.21 $ 0.55

SCHEDULE OF STOCK OPTIONS ACTIVITY

	Number of Options			Exercise Price per Share		Weighted Average Exercise Price per Share
Outstanding as of January 1, 2022		668,000		$	0.001 - 1.21	$	0.55
Granted		—			—		—
Exercised		—			—		—
Options forfeited/cancelled		—			—		—
Outstanding as of March 31, 2022		668,000		$	0.001 - 1.21	$	0.55

Outstanding as of January 1, 2023		524,000		$	0.001 - 0.95	$	0.44
Granted		—			—		—
Exercised		—			—		—
Options forfeited/cancelled		(48,000	)		0.15 – 0.32		0.16
Outstanding as of March 31, 2023		476,000		$	0.001 - 0.95	$	0.47

The following table summarizes information about stock options that are vested or expected to vest at March 31, ~~2022:~~2023:

Options Outstanding Exercisable Options
Exercise Price Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value
$ 0.001 90,000 $ 0.001            1.70 $ 0 90,000 $ 0.001 1.70 $ 0
0.05 3,000 0.05            1.50 0 3,000 0.05 1.50 0
0.15 90,000 0.15            1.08 0 90,000 0.15 1.08 0
0.18 45,000 0.18            1.58 0 45,000 0.18 1.58 0
0.19 45,000 0.19            2.08 0 45,000 0.19 2.08 0
0.20 48,000 0.20            1.79 0 48,000 0.20 1.79 0
0.31 3,000 0.31            0.75 0 3,000 0.31 0.75 0
0.32 3,000 0.32            1.00 0 3,000 0.32 1.00 0
0.73 3,000 0.73            0.58 0 3,000 0.73 0.58 0
0.61 45,000 0.61            0.50 0 45,000 0.61 0.50 0
0.95 200,000 0.95            0.45 0 200,000 0.95 0.45 0
1.09 3,000 1.09            0.25 0 3,000 1.09 0.25 0
1.10 45,000 1.10            0.33 0 45,000 1.10 0.33 0
1.21 45,000 1.21            0.08 0 45,000 1.21 0.08 0
$ 0.001-1.21 668,000 $ 0.55 0.97 $ 0 668,000 $ 0.55 0.97 $ 0

SCHEDULE OF STOCK OPTION VESTED

				Options Outstanding								Exercisable Options
Exercise Price		Number of Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value		Number of Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
$	0.001		90,000	$	0.001		0.95	$	38,160		90,000	$	0.001		0.95	$	38,160
	0.05		3,000		0.05		0.75		1,125		3,000		0.05		0.75		1,125
	0.15		45,000		0.15		0.58		12,375		45,000		0.15		0.58		12,375
	0.18		45,000		0.18		0.83		11,025		45,000		0.18		0.83		11,025
	0.19		45,000		0.19		1.33		10,575		45,000		0.19		1.33		10,575
	0.20		48,000		0.20		1.05		10,800		48,000		0.20		1.05		10,800
	0.95		200,000		0.95		1.26		—		200,000		0.95		1.26		—
$	0.001-1.21		476,000	$	0.47		1.08	$	84,060		476,000	$	0.47		1.08	$	84,060

There were no granted options granted, nor any options issued ~~between~~in the period ended March 31, ~~2022~~2023 and ~~December 31, 2021:~~ 2022:

The weighted-average remaining estimated life for options exercisable at March 31, ~~2022~~2023 is ~~0.97~~1.08 years.

The aggregate intrinsic value for fully vested, exercisable options was $084,060 at March 31, ~~2022~~2023 and at December 31, ~~2021~~2022 was ~~$0 as no options were exercised.~~$114,519. The actual tax benefit realized from stock option exercises for the three months ended at March 31, ~~2022~~2023 and ~~2021~~2022 was $0 as no options were exercised.

As at March 31, ~~2022~~2023 the Company has ~~34,041,909~~19,850,071 options or stock awards available for grant under the 2021 Plan.

NOTE 910 –NON-CONTROLLING INTEREST

~~Schedule of non-controlling interest~~SCHEDULE OF NON CONTROLLING INTEREST

	March 31, 2022			December 31, 2021			March 31, 2023			December 31, 2022
Net loss Subsidiary		(215,818	)		(2,089,253	)		(139,004	)		(817,151	)
Net loss attributable to the non-controlling interest		51,116			496,297			32,894			193,372
Net loss affecting Bioxytran		(164,702	)		(1,592,956	)		(106,110	)		(623,780	)

Accumulated losses		(2,992,953	)		(2,777,135	)		(3,733,291	)		(3,594,287	)
Accumulated losses attributable to the non-controlling interest		609,322			558,206			784,472			751,578
Accumulated losses Bioxytran		(2,383,631	)		(2,218,929	)		(2,948,819	)		(2,842,709	)

Net equity non-controlling interest		(448,372	)		(397,256	)		(623,522	)		(590,628	)

As at March 31, ~~2022~~2023 and at December 31, 2022 there are 30,000,000 issued and 19,650,000 outstanding shares; 15,000,000 Common shares are held by Bioxytran and 4,650,000 Common shares are held by an affiliate. An additional 4,500,000 options are also held by an affiliate. The option agreements include provisions for dilutive issuance and cash-less exercise.

NOTE 1011 – COMMITMENTS AND CONTINGENCIES

Employment contracts

~~The Company’s executive officers~~Our Executive Officers have entered into employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The ~~employment agreements~~most substantial provisions include;

	●	Compensation of three (3) times the employee’s annual salary upon the Termination Date and any target bonus earned, or if termination occurs within 12 months of a change in control, then the terminated employee shall receive two (2) times the employee’s annual salary and any target bonus earned.

	●	Continued coverage under any health, medical, dental or vision program or policy, in which they were eligible to participate at the time of employment termination, for 12 months.

	●	Provide outplacement services through one or more outside firms of the employee’s choosing up to an aggregate of $50,000.

There are no other arrangements or plans in which we provide ~~for the payment of $100,000~~ ~~in severance upon termination of employment without cause and make no provisions~~pension, retirement or similar benefits for any ~~payment upon a change~~ of ~~control.~~

Executive Officers or Directors.

~~Litigation~~

Litigation

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.

NOTE 1112 – SUBSEQUENT EVENTS

The Company has evaluated events from March 31, ~~2022~~2023 through the date the financial statements were issued. The events requiring disclosure for this period are as follows;

Extension of Maturity of Convertible Notes

On April 28 the Company extended the Maturity of a $1,000,000 convertible note to August 31, 2023

On May 10, 2023 the Company extended the Maturity of three (3) convertible notes for a value of $1,165,000 to April 30, 2024. The interest rate was renegotiated to 10%, from the former 6%, and the Company received the right to repurchase the note at 120% of face-value plus interest, after 60 days of the extension.

For the brokerage of the deal, our Investment Banker was compensated with 800,0005-year warrants exercisable at $0.20/share, valued at $0.4358, based on Black and Scholes Option Pricing Model, for a total value of $348,637.

Common ~~stock~~Stock

Shares issued in private placement

Cash Investment

On April 18, 2023 the Company issued 78,125 shares of Common Stock against $25,000, or $0.32/share.

Debt Restructure

On April 14, 2023, the transactions set forth below were approved by the Company’s Board of Directors with an objective to reduce the Company’s debt at a price equal to the Company’s Private Placement Memorandum (“PPM”) currently in place, or $0.32/share.

137,656 shares of Common Stock were issued against supplier invoices amounting to $44,050.

6,763,562 shares of Common Stock were issued to offset an affiliate against invoices paid on behalf of the Company and accrued salaries to our Officers, for a total value of $2,164,340.

Shares Awarded ~~and Issued~~ under the ~~2022~~2021 Stock Plan:

On April ~~1, 2022~~18, 2023 the Company ~~granted~~issued ~~10,000~~80,000 shares of Common Stock, awarded in January 2023, to ~~a Medical Advisory~~four Board ~~Member for her contribution to the Company~~Members in reward of their attendance at Board and Committee meetings during the ~~first~~fourth quarter of 2022. The total fair market value at the time of the award was $~~1,730~~38,400, or $~~0.173~~0.48/share.

On April ~~1, 2022~~18, 2023 the Company ~~granted~~issued ~~70,000~~2,000 shares of Common Stock, awarded in January 2023, to ~~four~~an Advisory Board Members in compensation for the fourth quarter of 2022. The total fair market value at the time of the award was $960, or $0.48/share.

On April 18, 2023 the Company issued 30,000 shares of Common Stock, awarded in January 2023, to three Board Members in reward of their attendance at Board and Committee meetings during the first quarter of ~~2022.~~2023. The total fair market value at the time of the award was $~~12,110~~12,750, or $~~0.173~~0.425/share.

On April ~~11, 2022~~18, 2023 the Company ~~granted~~issued ~~250,000~~2,000 shares of Common Stock, awarded in January 2023, to ~~three Consultants~~an Advisory Board Members in compensation for the ~~management~~first quarter of ~~our clinical trials in India.~~2023. The total fair market value at the time of the award was $~~43,250~~850, or $~~0.173~~0.425/share.

Management sees no further subsequent events requiring disclosure.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis is based on, and should be read in conjunction with, the audited financial statements and the notes thereto for the two years ended December 31, ~~2021~~2022 included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on ~~April 11, 2022.~~March 31, 2023. This discussion contains forward-looking statements. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

Overview

We do not currently have sufficient capital resources to fund operations. To stay in business and to continue the development of our products, we will need to raise additional capital through public or private sales of our securities, debt financing or short-term bank loans, or a combination of the foregoing. We believe that if we can raise $3,700,000, we will have sufficient working capital to repay the convertible notes and develop our business over the next approximately 15 months. At funding raised that is significantly less than $3,700,000, we can likely repay the ten convertible notes and continue to develop our business over the same 15-month period, but funding at that level will delay the development of our technology and business.

Bioxytran, Inc. is headquartered in ~~Newton,~~Needham, Massachusetts. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for stroke. BXT-25 will be designed to be an injectable anti-necrosis drug specifically designed to treat a person immediately after that person suffers an ischemic stroke. The drug is designed to be injected intravenously to travel to the lungs to pick up oxygen molecules to carry to the brain. Like a red blood cell, the drug will cross the blood brain barrier, which is a protective semi-permeable membrane allowing some material to cross but preventing others from crossing. BXT-25 will be designed to diffuse oxygen into the brain tissues. We expect the BXT-25 molecule to be 5,000 times smaller than a red blood cell.

Our ~~Subsidiary~~subsidiary, Pharmalectin Inc. (“Pharmalectin” or the “Subsidiary”), of which we currently have 85% ownership, is ~~continuing our clinical trials with~~focused on the development, manufacturing and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin has developed a novel method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Our lead drug candidate, named ~~ProLectin~~ProLectin-Rx, is a complex polysaccharide derived from ~~galactomannan and~~ pectin ~~respectively,~~ that binds to, and blocks the activity of galectin-1, ~~and -3,~~ a type of galectin. Galectins are a member of a family of proteins in the body called lectins. These proteins interact with carbohydrate sugars located in, on the surface of, and in between cells. This interaction causes the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain, or CRD, within the lectin. Galectins are a subfamily of lectins that have a CRD that bind specifically to ß-galactoside proteins. Galectins have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections galectins are upregulated and downregulated based on the type of virus.

~~ProLectin-M’s clinical data shows non-toxicity and efficacy for treatment~~A Proof-of-Concept trial approved by the IRB at Mazumdar Shaw Medical Center, Narayana Health in Bangalore, India was finalized in October 2020. The results of ~~mild to moderate COVID-19. In our initial Phase I/II clinical~~the trial are described in our three peer-reviewed articles Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trial, published ~~as a peer-reviewed scientific report~~ in ~~the~~ Journal of Vaccines & ~~Vaccinations:~~Vaccination on December 30, 2020, ~~https://www.longdom.org/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial-61087.html~~ Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity~~The Company is currently working~~ published in the International Journal of Health Sciences on aJuly 14, 2022 and PLG-007 and Its Active Component Galactomannan-α Competitively Inhibit Enzymes That Hydrolyze Glucose Polymers published in the International Journal of Molecular Science on July 13, 2022.

Results from our latest Phase ~~III~~2 trial on COVID-19 Patients published in medRxiv Galectin approach to lower covid transmission - Drug Development for clinical use on November 16, 2022, show positive topline safety and efficacy results of its randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the ~~CDCSO~~7 days of treatment, an orally administered Galectin Antagonist in ~~India,~~the form of a chewable tablet was administered 8 times per day on an hourly basis. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value = .001). Our analysis also revealed an 88% response rate by day 3, which was statistically significant (p-value = .001). There were no drug-related serious adverse events (SAE’s) in the patient population or viral rebounds by day 14 in the patient population.

On December 2, 2022, India’s Central Drugs Standard Control Organisation (CDSCO) issued an IND with permission to conduct: “A Phase 1b/2a Randomized, Blinded, placebo-controlled Study in Participants with Mild to Moderate COVID-19 to Evaluate the Safety, Efficacy, and ~~is preparing its~~Pharmacokinetics of Orally Administered ProLectin-M”. The study will continue by the filing of an Emergency IND ~~for a Phase III clinical trial~~ with the FDA ~~soon to be followed by a Phase III submission~~in the first quarter of 2023, provided we obtain adequate funding. An IND was consecutively filed with the ~~EMEA. The clinical trials are expected to take place~~FDA on March 13, 2022.

On January 27, 2023, an additional IND with the CDSCO was issued for an IV treatment of SARS-CoV-2 in ~~May through July, 2022. Further, the Company is also preparing an IND for~~moderate (Hospitalized patients) Covid-19 infections (ProLectin-I), Long Covid, and of treatment of lung-fibrosis as a ~~second drug candidate ProLectin-I with similar galactin blocking capabilities as the oral drug, ProLectin-M, but IV-injectable for severe cases~~result of ~~COVID-19. The initial Phase I/II clinical trial is planned for April through June, 2022. The described clinical trials are subject to additional funding.~~use of ventilator in treatment of Covid-19 (ProLectin-F), respectively.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited resources and operating history. As described in Note 6 of the financial statements, the Company has currently ~~thirty-eight (38)~~four (4) convertible loans outstanding at a total face value of ~~$3,632,000.~~$2,165,000. As shown in the accompanying unaudited condensed consolidated financial statements, the Company had an accumulated deficit of ~~$9,665,938~~$12,002,683 as at March 31, ~~2022.~~2023. The accumulated deficit as at December 31, ~~2021~~2022 was ~~$8,753,668.~~$11,217,600.

The future of the Company is dependent upon its ability to obtain financing to develop its new business opportunities and support the cost of the drug development including clinical trials and regulatory submission to the FDA.

Potential Impact of the Covid-19 Pandemic in December 2020, a strain of novel coronavirus (now commonly known as Covid-19) was reported to have surfaced in Wuhan, China. Covid-19 has since spread rapidly throughout many countries, and, on March 12, 2021, the World Health Organization declared Covid-19 to be a pandemic. In an effort to contain and mitigate the spread of Covid-19, many countries, including the United States, Canada and China, have imposed unprecedented restrictions on travel, and there have been business closures and a substantial reduction in economic activity in countries that have had significant outbreaks of Covid-19. Covid-19 may have a future material impact on our results of operation with respect to product development and clinical trials. However, significant uncertainty remains as to the potential impact of the Covid-19 pandemic on our operations, and on the global economy as a whole. It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. We do not yet know the full extent of any impact on our business or our operations, however, we will continue to monitor the Covid-19 situation closely, and we intend to follow health and safety guidelines as they evolve.

Management plans to seek additional capital through private placements and public offerings of its common stock. There can be no assurance that the Company will be successful in accomplishing its objectives. Without such additional capital or the establishment of strategic relationships with established pharmaceutical companies, the Company may be required to cease operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue operations.

~~Results of Operations~~RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2023 and 2022

We are a ~~start-up~~clinical stage company. Historically, ~~the Company~~Bioxytran was engaged in formation, fund raising and identifying and consulting with the scientific community regarding the development, formulation and testing of its ~~products.~~products as of the fourth quarter of 2021 the Company has engaged in research and development activities through its Subsidiary, Pharmalectin, Inc., developing the ProLectin-Rx.

~~Operating Expenses~~

Research and Development ~~(R&D) expenses for~~

	Three months ended
	March 31, 2023		March 31, 2022
Research and development:
Process development	$	—	$	—
Product development		—		58,888
Regulatory		57,004		76,592
Clinical trials		64,000		48,850
Project management		18,000		55,795
Total research and development	$	139,004	$	240,125

During the ~~3-months ended March 31, 2022 were $240,125, while for 3~~three months ended March 31, ~~2021, they were $347,033.~~

~~General and administrative (G&A) expenses for~~2023, the Company recorded $139,004 in R&D expenses. During the three months ended March 31, 2022, ~~were $556,581, while for~~ the ~~three months ended March 31, 2021, they were $567,320.~~Company recorded $240,125. The ~~components~~significant difference is due to a lack of ~~G&A expenses are as follows:~~funding.

General and Administrative

	Three months ended
	March 31, 2023		March 31, 2022
General and administrative expenses:
Payroll and related expenses	$	359,142	$	394,614
Costs for legal, accounting and other professional services		43,113		4,825
Promotional expenses		165,251		117,200
Miscellaneous expenses		30,132		39,942
Total general and administrative	$	597,638	$	556,581

●

Payroll and related expenses for the three months ended March 31, ~~2022~~2023 were ~~$377,114, as~~$359,142 compared to ~~$54,000~~$394,614 for the three months ended March 31, ~~2021. The difference was due a to market-based salary adjustment in June 2021.~~2023.

	●	The Costs for legal, accounting and other professional services for the three and Three months ended March 31, 2023 increased due to a refund of consulting fees in the first quarter of 2022.
	Promotional expenses for the Three months ended March 31, 2023 were $165,251, as compared to $117,200 for the Three months ended March 31, 2022. The increase costs stock promotion incurred by the Company’s return to being listed on OTCQB.
	Miscellaneous G&A expenses during the three months ended March 31, 2023 and 2022 ~~were $22,325, as compared~~was $30,132 and $39,942, respectively. The difference is due to ~~$39,123 for~~a temporary warehouse space in the first three months ~~ended March 31, 2021. The decrease was due to the limited use~~ of ~~the General Counsel.~~2022

●

Sales and marketing expense for the three months ended March 31, 2022 were $117,200, as compared to $3,500 for the three months ended March 31, 2021. The Company contracted a PR company in view of the upcoming re-list on OTC.

●

The remaining miscellaneous G&A expenses totaled $39,942 for the three months ended March 31, 2022, as compared to $470,697, including a $420,750 summary judgement against the Company, for the three months ended March 31, 2021. The claim from the judgement was later abandoned.

Stock-based Compensation

	Three months ended
	March 31, 2023		March 31, 2022
Compensation expense to BoD and Management	$	12,750	$	6,400
Compensation expense to consultants		850		16,000
Total compensation expense	$	13,600	$	22,400

Stock-based compensation mounted to ~~$22,400~~$13,600 for the three months ended March 31, ~~2022.~~2023. The stock-based compensation for the three months ended March 31, ~~2021~~2022 was ~~$774,558. The decrease was due to~~$22,400.

Other expenses

	Three months ended
	March 31, 2023		March 31, 2022
Other (expenses):
Interest expense		67,221		52,035
Debt discount amortization		—		49,084
Amortization of warrants		—		42,250
Amortization of IP		514		911
Total other income (expenses)	$	67,735	$	144,280

During the ~~liquidation~~three months ended March 31, 2023, the Company recorded an interest expense of $67,221 and $514 in amortization of the ~~2010 Stock Plan in January 2021.~~

~~Interest Expense and Amortization of Debt Discount and Premium~~

company’s IP. During the three months ended March 31, 2022, the Company ~~amortized $92,245 (consisting of~~recorded $49,084 in amortization of debt discount and $42,250 in issuance of warrants in connection with a capital raise while the interest expense was $52,035 and $911 ~~of IP). For~~was amortized from the ~~three months ended in March 31, 2021, the Company didn’t record any amortization. The interest for the convertible notes outstanding amounted to $52,035, as compared to $87,410 for~~Company’s IP.

Non-Controlling Interest

	Three months ended
	March 31, 2023		March 31, 2022
Net loss attributable to the non-controlling interest	$	32,894	$	51,116

For the three months ended March 31, ~~2021.~~

~~Non-Controlling Interest~~

~~For the three months ending March 31,~~2023 and 2022 there was a non-controlling interest attribution of ~~$51,116. For~~$32,894 and 51,116 respectively. The significant difference is due to a significant reduction in the ~~three months ending March 31, 2022~~R&D activities in the ~~company recorded a non-controlling interest attribution~~current year due to lack of ~~$154,614~~capital.

	# of shares		# of options		March 31, 2023		December 31, 2022
Minority owners cash investment		4,650,000			$	160,485	$	160,485
Bioxytran interest in subsidiary		15,000,000				1,500		1,500
Issued stock options @ $0.33				4,500,000		450		450
Total oustanding		19,650,000		4,500,000	$	162,435	$	162,435

There are currently 30,000,000 issued and 19,650,000 outstanding shares; 15,000,000 Common shares (76%) are held by Bioxytran and 4,650,000 Common shares (24%) are held by an affiliate. An additional 4,500,000 options are also held by an affiliate. The option agreement includes provisions for dilutive issuance and cash-less exercise. The beneficial ownership of the affiliate includes Mike Sheikh, Ola Soderquist and David Platt.

Net Loss

	Three months ended
	March 31, 2023			March 31, 2022
Net loss attributable to Bioxytran	$	(785,083	)	$	(912,270	)

Loss per common share, basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average number of common shares outstanding, basic		123,495,291			110,840,998

The Company generated a net loss for the three months ended March 31, ~~2022~~2023 of ~~$912,270.~~$785,083. In comparison, for the three months ended March 31, ~~2021,~~2022, the Company generated a net loss of ~~$1,621,707.~~$912,270. The ~~decreased loss~~significant difference is ~~a result of the summary judgement against the Company, the commencement of Research & Development as well as the liquidation of the 2010 Stock Plan.~~

~~Cash-Flows~~

~~Net cash used in operating activities was $691,411 and $391,100 for the three months ended March 31, 2022 and 2021, respectively. The decrease was~~ due to ~~Research and Development where~~a significant reduction in the ~~clinical trials were temporarily suspended for~~R&D activities in the current year due to lack of ~~patients.~~capital.

In the three months ended March 31, 2022 the Company is in the process of filing a patent, and $22,323 was spent in legal fees. In the three months ended March 31, 2021 the Company was in the process of filing a patent, and $8,953 was spent in legal fees.CASH-FLOWS

	Three months ended
	March 31, 2023			March 31, 2022
Net cash used in operating activities	$	(186,890	)	$	(691,411	)

Net cash used in investing activities		(4,711	)		(22,323	)

Net cash provided by financing activities		50,000			1,380,960

Net increase (decrease) in cash	$	(141,600	)	$	667,226
Cash, beginning of period		295,401			72,358
Cash, end of period		153,801			739,584

	Net cash used in operating activities was $186,890 and $691,411 for the Three months ended March 31, 2023 and 2022, respectively. The decrease was due to a reduction of the research and development activities due to lack of funding.
	In the Three months ended March 31, 2023 the Company is in the process of filing a patent, and $4,711 was spent in legal fees. In the Three months ended March 31, 2022 the amount was $22.323.
	Cash flows from financing activities were $50,000 and $1,380,960 for the Three months ended March 31, 2023 and 2022, respectively.
	The available cash was $153,801 and $739,584 in the end of the Three months ended March 31, 2023 and 2022, respectively.

~~Cash flows from financing activities were $1,380,960 and $450,000 for the three months ended March 31, 2022 and 2021, respectively. The significant change was an increase in convertible debt.~~

~~Available cash was $739,584 and $91,635 at March 31, 2022 and March 31, 2021, respectively.~~

LIQUIDITY AND CAPITAL RESOURCES

Current Assets

	March 31, 2023		December 31, 2022
Current assets:
Cash	$	153,801	$	295,401
Total current assets	$	153,801	$	295,401

As atof March 31, ~~2022,~~2023, our current assets consisted of ~~was $739 584~~$153,801 in cash ~~and $68,343~~at December 31, 2022 we had $295,401 in ~~intangible assets in the form of capitalized patent expenses. We~~cash.

Current Liabilities

	March 31, 2023		December 31, 2022
Current liabilities:
Accounts payable and accrued expenses	$	975,227	$	749,395
Accounts payable related party		1,100,869		709,727
Un-issued shares liability		1,810		960
Un-issued shares liability related party		51,150		38,400
Convertible notes payable, net of discount		2,165,000		2,165,000
Total current liabilities		4,294,056		3,663,482

At March 31, 2023 we had total liabilities of ~~$4,887,086, which were all current liabilities, and~~$4,294,056, which consisted of ~~$1,312,646~~$2,076,095 in accounts payable and accrued expenses (of which ~~$796,506~~$1,100,869 was payable to related parties), $52,960 in un-issued shares (of which $51,150 was payable to related parties), and ~~$3,552,225~~$2,165,000 in ~~the form of~~four convertible ~~loans and $22,400 in liability for un-issued shares (whereof $6,400 to related party). The equivalent numbers at~~loans. At December 31, ~~2021, our assets consisted of was $72,358 in cash and $46,931 in intangible assets in the form of capitalized patent expenses. We had~~2022 total liabilities were $3,663,482, consisting of ~~$3,277,497, which were all current liabilities, and which consisted of $1,155,316~~$1,459,121 in accounts payable and accrued expenses (of which ~~$531,000~~$709,727 was payable to related parties), $39,360 in un-issued shares (of which $38,400 was payable to related parties) and ~~$2,122,181~~$2,165,000 in the form of four convertible ~~loans.~~loans net of discount. More details on the account payables can be found under Notes 6 and 7 in the Financial Statements.

Net Working Capital and Accumulated Deficit

	March 31, 2023			December 31, 2022
Net working capital	$	(4,140,255	)	$	(3,368,081	)

Accumulated deficit	$	(12,002,683	)	$	(11,217,600	)

At March 31, 2023, the net working capital was negative $4,140,255 and the accumulated deficit of $12,002,683. Comparatively, on December 31, 2022, we ~~have total~~had net working capital of negative ~~$4,147,687~~$3,368,081 and an accumulated deficit of ~~$9,665,939. Comparatively, at December 31, 2021, we had total working capital~~$11,217,600. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of ~~negative $3,205,139 and an accumulated deficit of $8,753,669.~~June 2023. We believe that we must raise not less than $3,700,000 ~~in addition to current cash on hand~~ to be able to continue our business operations for ~~approximately~~ the next 15 months.

Cash Proceeds from Financing Activities

	Three months ended
	March 31, 2023		March 31, 2022
Cash proceeds from financing activities
Proceeds from stock transactions	$	50,000	$	—
Proceeds from issuance of convertible notes payable		—		1,380,461
Net cash provided by financing activities	$	50,000	$	1,380,461

During the Three months ending March 31, 2023, the Company had raised $50,000 through issuance of common shares. In the period ended March 31,2022 the company entered agreements for thirty-eight (38) convertible notes at 6% interest, with net cash proceeds of $1,380,461.

Upcoming Financing Activities

The Company intends to issue a Private Placement Offering under Regulation D in the order of $6 million in the spring of 2023.

There can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and ~~repay the ten convertible notes.~~implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

~~Future Financing~~Commitments

We have no current commitment from our officers and directors or any of our shareholders, to supplement our operations or provide us with financing in the future. If we are unable to raise additional capital from conventional sources and/or additional sales of stock in the future, we may be forced to curtail or cease our operations. Even if we are able to continue our operations, the failure to obtain financing could have a substantial adverse effect on our business and financial results. In the future, we may be required to seek additional capital by selling debt or equity securities, selling assets, or otherwise be required to bring cash flows in balance when we approach a condition of cash insufficiency. The sale of additional equity or debt securities, if accomplished, may result in dilution to our then shareholders. We provide no assurance that financing will be available in amounts or on terms acceptable to us, or at all.

~~Contractual Obligations~~

As at March 31, 2022, our contractual obligations include two sets of convertible notes, with a face value of $3,632,000 and of accrued interest for these notes mounting to $137,720, described under Note 6 to the Financial Statements.

The Company’s executive officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements provide for the payment of $100,000 in severance upon termination of employment without cause and make no provisions for any payment upon a change of control.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.

CRITICAL ACCOUNTING POLICIES

In presenting our financial statements in conformity with generally accepted accounting principles, we are required to make estimates and assumptions that affect the amounts reported therein. Several of the estimates and assumptions we are required to make relate to matters that are inherently uncertain as they pertain to future events. However, events that are outside of our control cannot be predicted and, as such, they cannot be contemplated in evaluating such estimates and assumptions. If there is a significant unfavorable change to current conditions, it could result in a material adverse impact to our results of operations, financial position and liquidity. We believe that the estimates and assumptions we used when preparing our financial statements were the most appropriate at that time. Presented below are those accounting policies that we believe require subjective and complex judgments that could potentially affect reported results. However, the majority of our businesses operate in environments where we pay a fee for a service performed, and therefore the results of the majority of our recurring operations are recorded in our financial statements using accounting policies that are not particularly subjective, nor complex.

Stock Based Compensation

The Company has share-based compensation plans under which non-employees, consultants and suppliers may be granted restricted stock, as well as options to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award over the requisite service period.

The Company applies ASC 718 for options, common stock and other equity-based grants to its employees and directors. ASC 718 requires measurement of all employee equity-based payment awards using a fair-value method and recording of such expense in the consolidated financial statements over the requisite service period. The fair value concepts have not changed significantly in ASC 718; however, in adopting this standard, companies must choose among alternative valuation models and amortization assumptions. After assessing alternative valuation models and amortization assumptions, the Company will continue using both the Black-Scholes valuation model and straight-line amortization of compensation expense over the requisite service period for each separately vesting portion of the grant.

Recent Accounting Standards

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2021. The adoption of AASU 2020-06 did not have an impact on the Company’s financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 3 is not applicable to us because we are a smaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer) reviewed the effectiveness of our disclosure controls and procedures as at the end of the period covered by this report and concluded that as at March 31, ~~2022,~~2023, (i) the Company’s disclosure controls and procedures were not effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “Commission”), and (ii) the Company’s controls and procedures have not been designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934,

as amended, is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based on this evaluation, our principal executive officer and principal financial officer concluded as at the evaluation date that our disclosure controls and procedures were not effective due primarily to a material weakness in the segregation of duties in the Company’s internal controls.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management assessed the effectiveness of our internal control over financial reporting as of March 31, ~~2022.~~2023. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

As disclosed in our previous filings, there are material weaknesses in the Company’s internal control over financial reporting due to the fact that the Company does not have an adequate process established to ensure appropriate levels of review of accounting and financial reporting matters, which resulted in our closing process not identifying all required adjustments and disclosures in a timely fashion. The Company’s CEO/CFO has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation.

Although the Company has hired a consultant to assist with SEC reporting and accounting matters, we expect that the Company will need to hire accounting personnel with the requisite knowledge to improve the levels of review of accounting and financial reporting matters. The Company may experience delays in doing so and any such additional employees would require time and training to learn the Company’s business and operating processes and procedures. For the near-term future, until such personnel are in place, this will continue to constitute a material weakness in the Company’s internal control over financial reporting that could result in material misstatements in the Company’s financial statements not being prevented or detected.

Because of the above material weakness, management has concluded that we did not maintain effective internal control over financial reporting as of March 31, ~~2022,~~2023, based on the criteria established in “Internal Control-Integrated Framework” issued by the COSO.

No Attestation Report by Independent Registered Accountant

The effectiveness of our internal control over financial reporting as of March 31, ~~2022~~2023 has not been audited by our independent registered public accounting firm by virtue of our exemption from such requirement as a smaller reporting company.

Changes in Internal Controls Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the 3 months ended March 31, ~~2022~~2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

The Company’s management does not expect that its disclosure controls or its internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

The Company may become involved in certain legal proceedings and claims which arise in the normal course of business.

On June 5, 2020 the Supreme Court of the State of New York, County of Nassau, issued a commencement of Action based on behalf of Power Up Lending Group, Ltd (“Power Up” or the “Claimant”). The claimant request that due to the default of their note requesting a judgment for an amount of not less than $420,750. Among other claims Power Up asserts that the Company willfully failed to maintain the trading status, and manipulated its stock in its efforts to defraud the public and its investors by making false press statements and the like. The Company is denying any wrong-doing. On January 20, 2021 the Supreme Court of the State of New York, County of Nassau, granted Power Up a summary judgement against the Company for Breach of Contact, awarding Power Up damages in the amount of $420,750.

The underlying convertible note was, per agreement of the parties, cancelled on June 4, 2021, with Power Up agreeing to a stipulation of discontinuance with prejudice of the law-suite and forfeiture of earlier awarded damages.

Item 1A. Risk Factors

The company is a smaller reporting company and is not required to provide this information.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On February 10, 2023 the Company issued 156,250 shares of Common Stock against $50,000, or $0.32/share

~~There were no sales~~All funds received though these equity transactions will be used in the development of ~~equity securities sold during~~ the ~~period covered by this Report that were not previously included in a Current Report on Form 8-K.~~ProLectin-M, and for operating expenses.

The Company claims an exemption from the registration requirements of the Securities Act of 1933 (the “Securities Act”) for the private placement of these securities pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.

Item 3. Defaults Upon Senior Securities

There are currently no defaults upon Senior Securities.

However, on April 16, 2020, SEC ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading of BIXT is suspended for the period April 16 through April 29, 2020. As a result of the SEC ordered suspension the Company’s ten outstanding Convertible Notes went into default.

At May 26, 2021, the ten outstanding notes in default were returned to the Company in exchange for a 1-year 6% note with a principal of $1,000,000 by a Company affiliate. The net gain on the forgiveness, $1,020,323, was recorded as additional paid-in capital. The underlying convertible notes was, per agreement of the parties, cancelled on June 4, 2021.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

On March 30, 2022, FINRA finalized their review our 15c-211 filing and issued a Clearance Letter. OTC Markets are in the process of reviewing the removal of the Caveat Emptor symbol. A requirement for brokers to be able to offer our stock to a broader investor base. None

Item 6. Exhibits

Exhibit No.		Title of Document

~~31.1~~10.73*		Form of Private Purchase Agreement

10.74*		Form of Subscription Agreement

31.1*		Certification of Principal Executive and Financial Officers pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended. *

~~32.1~~32.1**		Certification pursuant to Section 906 of Sarbanes Oxley Act of 2002 (Chief Executive and Financial Officer). **

100		The following financial statements from the Quarterly Report on Form 10-Q of BIOXYTRAN, Inc. for the quarter ended March 31, ~~2022~~2023 formatted in XBRL: (i) Condensed Balance Sheets (unaudited), (ii) Condensed Statements of Operations (unaudited), (iii) Condensed Statements of Cash Flows (unaudited), and (iv) Notes to Condensed Financial Statements (unaudited), tagged as blocks of text. *

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*	Filed as an exhibit hereto.

**	These certificates are furnished to, but shall not be deemed to be filed with, the Securities and Exchange Commission.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

	BIOXYTRAN, INC.

Date: May ~~23, 2022~~ 12, 2023	By:	/s/ David Platt
		David Platt
		Chief Executive Officer

		/s/ Ola Soderquist
		Ola Soderquist
		Chief Financial Officer


	3-Months Ended
	March 31, 2022			March 31, 2021
Operating expenses:
Research and development	$	240,125		$	347,033
General and administrative		556,581			567,320
Compensation expense		22,400			774,558
Total operating expenses		819,106			1,688,911

Loss from operations		(819,106	)		(1,688,911	)

Other expenses:
Interest expense		52,035			87,410
Amortization		92,245			—
Total other expenses		144,280			87,410

Net loss before provision for income taxes		(963,386	)		(1,776,321	)

Provision for income taxes		—			—
Net loss		(963,386	)		(1,776,321	)

Net loss attributable to the non-controlling interest		51,116			154,614

NET LOSS ATTRIBUTABLE TO BIOXYTRAN	$	(912,270	)	$	(1,621,707	)

Loss per common share, basic and diluted	$	(0.01	)	$	(0.02	)

Weighted average number of common shares outstanding, basic and diluted		110,840,998			100,118,229

	Estimated Life (years)		March 31, 2022			December 31, 2021
Capitalized patent costs		20	$	69,254		$	46,931
Accumulated amortization				(911	)		—

Intangible assets, net			$	68,343		$	49,931

	March 31, 2022		December 31, 2021
Accounts payable related party ⁽¹⁾	$	796,506	$	531,000
Professional fees		120,696		375,371
Other		1,155		—
Interest		137,720		85,685
Payroll taxes		59,693		32,010
Pension/401K		196,875		131,250
Un-issued share liability, consultant		16,000		—
Un-issued share liability, related party ⁽²⁾		6,400		—
Convertible note payable		3,552,225		2,122,181
Total	$	4,887,270	$	3,277,497

Name		Principal due March 31, 2022		Accrued interest March 31, 2022		Total amount due March 31, 2022
Private Placement, 2021 Notes	(1)	$	2,165,000	$	118,160		2,283,160
Private Placement, 2022 Notes	(2)		1,467,000		19,560		1,486,560
		$	3,632,000	$	137,720		3,769,720

⁽¹⁾ $1,000,000 of this amount was used to extinguish the Old Notes. Net cash received for these notes were $1,045,150, after a Debt Discount of $119,850 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).
⁽²⁾ Net cash received for these notes were $1,380,960, after a Debt Discount of $86,040 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).

Name		Principal due December 31, 2021		Accrued interest December 31, 2021		Total amount due December 31, 2021
Notes sold in exchange for cash	(1)	$	1,165,000	$	46,108		1,211,108
Note issued in exchange for defaulted Old Notes	(2)		1,000,000		39,577		1,039,577
		$	2,165,000	$	85,685		2,250,685

(3) Net cash received for these notes were $1,045,150, after a Debt Discount of $119,850 was paid to the sole Placement Agent: WallachBeth Capital, LLC (Member FINRA / SIPC).
(4) The "Old Notes" were paid off and assumed by a different entity/company. Portions of the balance was forgiven and a new note of $1,000,000 was issued.

	March 31, 2022			December 31, 2021
Principal balance	$	3,632,000		$	2,165,000
Unamortized debt discount		(79,775	)		(42,819	)
Outstanding, net of debt discount and premium	$	3,552,225		$	2,122,181

	Number of Warrants		Weighted Average Exercise Price		Weighted- Average Remaining Expected Term
Outstanding as at December 31, 2021		272,000	$	2.00		3.9
Granted		—		—		—
Exercised		—		—		—
Forfeited/Canceled		—		—		—
Outstanding as at March 31, 2021		272,000		2.00		3.7

Outstanding as at December 31, 2022		272,000	$	2.00		2.9
Granted		264,060		0.25		5.0
Exercised		—		—		—
Forfeited/Canceled		—		—		—
Outstanding as at March 31, 2022		536,060	$	1.14		3.7

		Warrants Outstanding						Exercisable Warrants
Number of Warrants		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value	Number of Warrants		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
264,060		0.25	4.8	$	—	264,060		0.25	4.8	$	—
272,000	$	2.00	2.6	$	—	272,000	$	2.00	2.6	$	—
536,060	$	1.14	3.7	$	—	536,060	$	1.14	3.7	$	—

	Number of Warrants		Weighted- Average Grant-Date Fair Value
Non-vested as at December 31, 2022		—	$	—
Granted		264,060		0.25
Forfeited		0		0
Vested		264,060		0.25
Non-vested as at March 31, 2022		0	$	0

	Number of Shares		Fair Value per Share		Weighted Average Market Value per Share
Shares Issued as of December 31, 2020		11,002,000	$	0.003 – 1.49	$	0.10
Shares Issued		3,199,200		0.24		0.24
Shares Issued as of March 31, 2021		14,201,200	$	0.003 – 1.49	$	0.13

Shares Issued as of December 31, 2021		18,706,909		0.003 – 1.49		0.088
Shares Issued		—		—		—
Shares Issued as of March 31, 2022		18,706,909	$	0.003 – 1.49	$	0.088

	Number of Options		Exercise Price per Share		Weighted Average Exercise Price per Share
Outstanding as of December 31, 2020		533,000	$	0.001 - 1.21	$	0.73
Granted		45,000		0.20		0.20
Exercised		—		—		—
Options forfeited/cancelled		—		—		—
Outstanding as of March 31, 2021		578,000	$	0.001 - 1.21	$	0.72

Outstanding as of December 31, 2021		668,000	$	0.001 - 1.21	$	0.55
Granted		—		—		—
Exercised		—		—		—
Options forfeited/cancelled		—		—		—
Outstanding as of March 31, 2022		668,000	$	0.001 - 1.21	$	0.55

					Options Outstanding						Exercisable Options
Exercise Price			Number of Options		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value	Number of Options		Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
$		0.001	90,000	$	0.001	1.70	$	0	90,000	$	0.001	1.70	$	0
		0.05	3,000		0.05	1.50		0	3,000		0.05	1.50		0
		0.15	90,000		0.15	1.08		0	90,000		0.15	1.08		0
		0.18	45,000		0.18	1.58		0	45,000		0.18	1.58		0
		0.19	45,000		0.19	2.08		0	45,000		0.19	2.08		0
		0.20	48,000		0.20	1.79		0	48,000		0.20	1.79		0
		0.31	3,000		0.31	0.75		0	3,000		0.31	0.75		0
		0.32	3,000		0.32	1.00		0	3,000		0.32	1.00		0
		0.73	3,000		0.73	0.58		0	3,000		0.73	0.58		0
		0.61	45,000		0.61	0.50		0	45,000		0.61	0.50		0
		0.95	200,000		0.95	0.45		0	200,000		0.95	0.45		0
		1.09	3,000		1.09	0.25		0	3,000		1.09	0.25		0
		1.10	45,000		1.10	0.33		0	45,000		1.10	0.33		0
		1.21	45,000		1.21	0.08		0	45,000		1.21	0.08		0
$	0.001-1.21		668,000	$	0.55	0.97	$	0	668,000	$	0.55	0.97	$	0